INmune Bio raises ~$4.8M in registered direct offering with warrants at 10% premium

Inmune Bio, Inc.

Gross proceeds ~$4.8M from sale of 571,592 shares and warrants at $8.32 per unit.
Warrant exercise price $9.152 (10% premium); warrants accelerate upon positive Phase 2 Alzheimer's top-line data.
Officers, directors, employees bought ~20% of offering at $8.445 per unit.
Net proceeds to fund Phase 2 Alzheimer's trial (XPro1595) and Phase 1 prostate cancer trial (INKmune).
Offering expected to close April 24, 2024; LifeSci Capital as sole placement agent.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Inmune Bio, Inc. entered into Placement Agency Agreement with LifeSci Capital LLC valued at Cash fee equal to 4% of gross proceeds from sale of shares and warrants (effective 2024-04-19).

Action: entry
Agreement: underwriting
Counterparty: LifeSci Capital LLC
Value: Cash fee equal to 4% of gross proceeds from sale of shares and warrants
Effective: 2024-04-19

Exact text from the filing

Pursuant to a placement agency agreement (the “Placement Agency Agreement”) dated as of April 19, 2024, between the Company and LifeSci Capital LLC (the “Placement Agent Agreement,” the Company engaged the Placement Agent to act as the Company’s sole placement agent in connection with the registered direct offering.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Inmune Bio, Inc. entered into Securities Purchase Agreement with Purchasers valued at 571,592 shares of common stock and warrants to purchase 571,592 shares at $8.32 per share and warran (effective 2024-04-19).

Action: entry
Agreement: equity purchase
Counterparty: Purchasers
Value: 571,592 shares of common stock and warrants to purchase 571,592 shares at $8.32 per share and warran
Effective: 2024-04-19

Exact text from the filing

On April 19, 2024, INmune Bio, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers set forth on the signature page thereto (the “Purchasers”) for the purchase and sale of an aggregate of 571,592 shares of the Company’s common stock (the “Shares”) and common stock warrants to purchase 571,592 shares of its common stock (“Warrants”) in a registered direct offering.

View on SEC.gov

306 material agreements filed in the last 30 days. Browse all material agreements →

Inmune Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-034982

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.